期刊档案 · 化学-医药化学

European Journal of Medicinal Chemistry

ISSN 0223-5234 · eISSN 1768-3254 · Elsevier Masson SAS · FRANCE · Monthly

European Journal of Medicinal Chemistry 中科院 医学 2区(2025 年升级版),影响因子 6.61,混合开放获取,APC 约 4,650 美元,近 24 个月 162 篇文章投稿到接收中位 65 天,录用比例约 较易来源Elsevier官网:32%(社区反馈),2025 年发文 1,195 篇,SCIE、Scopus 收录。

影响因子6.61LetPub 汇总的最新公布值
中科院分区医学 2区2025 年升级版大类 · 2026 新锐版 医学 2区
审稿周期65 天投稿到接收中位数 · 近 24 个月 162 篇文章 · PubMed
版面费4,650 USD混合期刊,仅开放获取发表时收取
录用比例较易来源Elsevier官网:32%投稿社区平均反馈
年发文量1,195 篇2025 年 · OpenAlex 统计

研究范围

研究范围与定位

European Journal of Medicinal Chemistry 由 Elsevier Masson SAS 出版,属中科院医学大类(2025 升级版2区)。按 OpenAlex 近年发文统计,该刊主要发表 Synthesis and biological activity、Synthesis and Biological Evaluation、Cancer therapeutics and mechanisms 等主题的论文,这 3 个主题约占 31.2%,主导子领域为 Organic Chemistry。(根据 OpenAlex 主题统计与中科院分区数据生成)

EJMECH (The European Journal of Medicinal Chemistry) is a global journal that publishes studies on the main aspects of medicinal chemistry. It provides a medium for publication of original research papers and it welcomes critical review papers.A typical paper would report on the design (with or without the support of computational methods), organic synthesis, characterization and biochemical/pharmacological evaluation of novel, potent compounds preferentially with a clear (or proven) mechanism of action and/or target. Other topics of interest are molecular aspects of drug metabolism, prodrug synthesis and drug targeting. The journal expects manuscripts to present a clear rational for a study, provide insight into the strategy and design of compounds and into the mechanism of action, and biological targets. Manuscripts reporting only computational studies are out-of-scope unless a new method (broadly applicable, validated and available to the community) is reported. Authors are kindly invited to look to published articles for the scope of the journal and the organisation of papers.

摘自期刊官网 Aims & Scope

研究方向(LetPub):化学-医药化学

主编 Paola Barraja出版商官网

编委会国家分布:中国大陆 12 位(约 31%);主要国家 中国 12、美国 7、印度 6、法国 4、中国台湾 2(共 39 位编委标注了国家) 编委会 ↗出版商官网 ·

主要研究主题 OpenAlex 近年发文统计,占比为近似值

  1. Synthesis and biological activityChemistry15.4%
  2. Synthesis and Biological EvaluationChemistry9.1%
  3. Cancer therapeutics and mechanismsBiochemistry, Genetics and Molecular Biology6.7%
  4. Computational Drug Discovery MethodsComputer Science5.9%
  5. Click Chemistry and ApplicationsChemistry5.5%
  6. Bioactive Compounds and Antitumor AgentsPharmacology, Toxicology and Pharmaceutics4.7%
  7. Synthesis and Characterization of Heterocyclic CompoundsChemistry4.6%
  8. Quinazolinone synthesis and applicationsChemistry3.9%

分区与收录

学科分区与数据库收录

中科院期刊分区表

期刊分区表( 2025年3月升级版)医学 2 区
类别学科分区
大类医学2 区
小类药物化学CHEMISTRY, MEDICINAL1 区

Top 期刊:否综述期刊:否

《新锐期刊分区表》( 2026年3月发布)医学 2 区
类别学科分区
大类医学2 区
小类药物化学CHEMISTRY, MEDICINAL2 区

Top 期刊:是综述期刊:未标注

期刊分区表( 2023年12月旧的升级版)医学 2 区
类别学科分区
大类医学2 区
小类药物化学CHEMISTRY, MEDICINAL1 区

Top 期刊:是综述期刊:否

数据库收录

SCIEScopusLetPub

国际期刊预警名单:各版本均未列入LetPub

不同版本、大类与小类分别展示,不将不同评价口径合并为一个分区值;投稿与考核前请确认所在机构采用的版本。

指标

影响力指标与发文规模

影响力指标

影响因子
6.61LetPub ·
影响因子(出版商公布)
6.7出版商官网 ·
CiteScore 2026-06
10.8LetPub ·
CiteScore(出版商公布)
10.8出版商官网 ·
SJR 2026-06
1.15LetPub ·
SNIP 2026-06
1.34LetPub ·
h-index
135LetPub ·
h-index
239OpenAlex ·
i10-index
13,832OpenAlex ·
两年平均被引
6.25OpenAlex ·
自引率
9%LetPub ·
Gold OA 文章占比
15.37%LetPub ·

发文规模

年文章数
1,042LetPub ·

逐年发文量 OpenAlex 统计 · 累计 19,244 篇 · 当年数据不完整

年份发文量其中 OA被引
2026755182381
20251,1953675,741
20241,01063512,372
202394361416,920
202288255919,765
202185454126,469

不同来源的统计口径与观测时间不同,页面保留各来源原值;“出版商公布”为期刊官网自述数据。

审稿与录用

审稿周期与录用情况

文章统计的审稿周期 PubMed 登记的稿件日期 · 至

65 天投稿到接收中位数 · P25–P75 48 天 – 93 天

接收到上线
中位数 4 天(162 篇)
投稿到上线
中位数 70 天
样本
162 篇有投稿与接收日期的文章(窗口内共 2,302 篇),最近一篇接收于

只统计最终被录用并发表的文章,不含被拒稿件的处理时间,因此通常长于出版商公布的"首次决定时间"。

其他来源

平均审稿速度(社区反馈)
平均4.3个月来源Elsevier官网:平均7.4周LetPub ·
平均录用比例(社区反馈)
32%LetPub ·
投稿到首次决定
2 天出版商官网 ·
外审后首次决定
21 天出版商官网 ·
投稿到接收
61 天出版商官网 ·
接收到发表
4 天出版商官网 ·
评审方式
单盲同行评审出版商官网

社区反馈来自投稿者样本,置信度 0.5,不代表期刊承诺;“出版商公布”的时间节点定义以官网为准。

费用与开放获取

版面费与开放获取政策

混合开放获取LetPub

订阅期刊,作者可付费选择开放获取发表。

来源文章处理费费用减免许可证观测时间
OpenAlexUSD 4,650 / EUR 4,350 / GBP 3,720 / JPY 576,740——
出版商官网USD 4,680——

混合期刊的文章处理费仅在作者选择开放获取发表时收取;按订阅方式发表通常不收费。

费用以期刊官网为准;不同来源的观测时间可能不同,页面保留各来源原值,不做平均。

投稿要求

文章类型与投稿政策(官网)

征稿中的专刊1 个,按截稿日期
  1. Natural products inspired enzyme inhibitors and agents for metabolic diseases截稿
出版商官网
接收的文章类型4 种
  1. original research articleThis journal accepts two types of manuscripts:Original Research articles:These articles present a complete study that is to say that they should contain the syn…未说明篇幅
  2. original research articlesOriginal Research articles: These articles present a complete study that is to say that they should contain the synthesis and evaluation of new compounds. The i…未说明篇幅
  3. reviewThis journal accepts two types of manuscripts:Original Research articles:These articles present a complete study that is to say that they should contain the syn…未说明篇幅
  4. review articleThis journal accepts two types of manuscripts:Original Research articles:These articles present a complete study that is to say that they should contain the syn…未说明篇幅
出版商官网
官网政策摘录AI 使用、作者资格、利益冲突、出版伦理、许可与版权、开放获取、同行评审、预印本
AI 使用 Declaration of generative AI use

Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…

原文 ↗出版商官网 ·
作者资格 Group authorship

Submission declaration: work not published previously except as preprint/abstract/lecture/thesis/registered report; not under consideration elsewhere; approval by all authors; not published elsewhere in same form without written consent of copyright-holder; manuscripts may be checked with screening 模型摘要

Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…

原文 ↗出版商官网 ·
利益冲突 Declaration of competing interests

All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …

原文 ↗出版商官网 ·
出版伦理

Authors must follow Elsevier's Publishing Ethics Policy. 模型摘要

Authors must follow ethical guidelines stated in Elsevier's Publishing Ethics Policy.

原文 ↗出版商官网 ·
许可与版权 License options

Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.

原文 ↗出版商官网 ·
开放获取 Open access

We refer you to our open access information page to learn about open access options for this journal.

原文 ↗出版商官网 ·
同行评审 Peer review

Single anonymized review process; initial editor assessment; typically a minimum of two reviewers; editors make the accept/reject decision; formal appeal requests allowed per Elsevier's Appeal Policy, one appeal per submission, appeal decision final. 模型摘要

This journal follows a single anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Re…

原文 ↗出版商官网 ·
预印本 Preprints

Preprint sharing allowed per Elsevier's article sharing policy and does not count as prior publication; free preprint posting service on SSRN offered; posting on SSRN is optional and has no effect on the editorial process or publication outcome. 模型摘要

Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication. In support of Open Science, this journal offers its authors a free preprint posting service on SSRN, Elsevier’s preprint and early research …

原文 ↗出版商官网 ·

摘录来自期刊官网页面,仅保留原文片段;“模型摘要”由 Workers AI 生成并经原文校验,以官网为准。

基本信息

出版信息与官方入口

出版商
Elsevier Masson SAS
出版国家或地区
FRANCE
出版语言
Multi-Language
出版周期
Monthly
ISSN
0223-5234
电子版 ISSN
1768-3254
官方链接

常见问题

关于 European Journal of Medicinal Chemistry 的常见问题

European Journal of Medicinal Chemistry 是中科院几区期刊?

2025 年升级版分区表中,European Journal of Medicinal Chemistry 为医学 2区,小类 药物化学 1 区。2026 年新锐版分区表中为医学 2区。不同版本与大小类分区不能混用。

European Journal of Medicinal Chemistry 的影响因子是多少?

LetPub 汇总的最新公布影响因子为 6.61,CiteScore 为 10.8,h-index 为 239。

European Journal of Medicinal Chemistry 的审稿周期多长?

按 2024年10月至2026年10月(近 24 个月)162 篇已发表文章登记的日期,投稿到接收的中位数为 65 天(四分位 48–93 天);投稿社区反馈的平均审稿速度为约 4.3 个月,平均录用比例反馈为“较易来源Elsevier官网:32%”。文章统计只含被录用的稿件,出版商数据口径以官网为准,社区反馈来自投稿者样本,均不代表期刊承诺。

European Journal of Medicinal Chemistry 的编委会里有中国学者吗?

期刊官网编委会页面上标注了国家的 39 位编委中,中国大陆 12 位(约 31%);人数最多的国家是 中国(12 位)、美国(7 位)、印度(6 位)。统计按编委会页面列出的机构国家计,仅供参考。

European Journal of Medicinal Chemistry 被哪些数据库收录?

据 LetPub 与 DOAJ 记录,European Journal of Medicinal Chemistry 被 SCIE、Scopus 收录。

European Journal of Medicinal Chemistry 是开放获取期刊吗?版面费多少?

European Journal of Medicinal Chemistry 为混合开放获取。选择开放获取发表时APC 约 4,650 美元。

来源与更新

本页事实来自 LetPub、出版商官网、OpenAlex;每个数字旁标注来源与观测日期,冲突数据保留各来源原值。LetPub 原始详情页:查看 ↗(2026-08-26 归档)。最近更新:。